Recipharm’s proprietary molecule Erdosteine recognised as COPD treatment

25 Nov 2018

Products containing Erdosteine from Recipharm are now marketed in over 40 countries across the world and is available in four different dosage forms.

Recipharm's proprietary molecule Erdosteine has been officially recognised by the GOLD (Global Initiative for Chronic Obstructive Lung disease) Scientific Committee as one of the commonly used maintenance medications in COPD (Chronic Obstructive Pulmonary Disease).

Recipharm’s proprietary molecule Erdosteine recognised as COPD treatment

Erdosteine, which was discovered and developed in Italy by Recipharm’s facility in Paderno Dugnano, has been listed in the 2019 GOLD report. Since its introduction in 2001, the GOLD report has become a leading worldwide reference for all healthcare professionals and health authorities for the effective diagnosis, management and prevention of COPD.

Products containing Erdosteine from Recipharm are now marketed in over 40 countries across the world and is available in four different dosage forms including a capsule, sachet, dispersible tablet and suspension. Recipharm supplies Erdosteine as both API and as finished dose form to its customers.

Pierfrancesco Manzo, Sales & Business Development Director for Erdosteine commented: “This is an important recognition of the scientific value of our molecule and it has been achieved thanks to the outcomes of the recent clinical studies which proved Erdosteine to be effective in the treatment of COPD patients. We are confident that Erdosteine is going to play an increasing role in the treatment of this pathology.”

The recognition in the GOLD report follows extensive research as part of the RESTORE study published in 2017, which saw 467 patients in ten countries undergo 12 months of treatment with positive results that support its clinical effectiveness.

Erdosteine’s pharmacological profile is characterised by unique multifactorial activity: muco-modulatory, anti-bacterial, anti-inflammatory and anti-oxidant. The chemical synthesis of the API and the manufacture of capsules and dispersible tablets is performed in Recipharm’s Paderno Dugnano facility, located just outside of Milan.

Read More

Related news

New gene therapy manufacturing facility for Orchard Therapeutics

New gene therapy manufacturing facility for Orchard Therapeutics

13 Dec 2018

Enhances company's capacity to develop and deliver lentiviral vector and gene-corrected hematopoetic stem cells for wide range of diseases on a global scale.

Read more 
WuXi AppTec expands site in California for pharmaceutical R&D services

WuXi AppTec expands site in California for pharmaceutical R&D services

13 Dec 2018

Expanded facility will establish a center of excellence in screening, discovery biology, pharmacology, and small molecule process R&D including Phase I GMP manufacturing.

Read more 
Cambrex expands analytical capabilities

Cambrex expands analytical capabilities

12 Dec 2018

The $1 million investment will assist in getting new products to commercial launch faster.

Read more 
Future-oriented packaging concepts from Sanner

Future-oriented packaging concepts from Sanner

11 Dec 2018

Company will showcase a range of packaging solutions, from desiccant and customized packaging to smart packaging solutions, at Pharmapack.

Read more 
One month on: medical cannabis is still taboo despite change in law

One month on: medical cannabis is still taboo despite change in law

11 Dec 2018

Restrictive guidelines have led many to buy CBD products online, leading to a boom in production with many products going to market without sufficient quality control.

Read more 
SGS to expand bioanalytical testing capabilities

SGS to expand bioanalytical testing capabilities

10 Dec 2018

The €3.5 million investment in equipment, facilities and expert staff will significantly increase the capabilities at the site to match increasing demand and shorten processes for pharmaceutical clients.

Read more 
MIT engineers repurpose wasp venom as an antibiotic drug

MIT engineers repurpose wasp venom as an antibiotic drug

9 Dec 2018

Altered peptides from a South American wasp’s venom can kill bacteria but are nontoxic to human cells.

Read more 
Spanish CDMO working ahead of EU serialisation deadline

Spanish CDMO working ahead of EU serialisation deadline

6 Dec 2018

Company now able to serialise commercial batches manufactured by them for clients; it can also offer standalone serialisation services as an outsourcing partner.

Read more 
Fluidic Analytics raises $31m to launch new lab tools and unlock biology behind major diseases

Fluidic Analytics raises $31m to launch new lab tools and unlock biology behind major diseases

5 Dec 2018

The financing will power the global commercial launch of the company's Fluidity One system.

Read more 
OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD

OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD

4 Dec 2018

The new treatment will leverage OnDosis’ proprietary technology, which integrates oral drugs in form of micro units and individualised dosing, in a handheld device.

Read more